期刊文献+

(R)-(-)-3-氯-1,2-丙二醇合成(R)-(-)-3-氯-2-羟丙基对甲苯磺酸酯的研究

Synthesis of Medicinal Intermediate(R)-(-)-3-chloro-2hydroxypropyl Tosylate from(R)-(-)-3-chloro-1,2-propanediol
在线阅读 下载PDF
导出
摘要 以(R)-(-)-3-氯-1,2-丙二醇为原料合成了医药中间体(R)-(-)-3-氯-2-羟丙基对甲苯磺酸酯,探讨了反应温度、反应时间、溶剂种类及用量、催化剂种类及用量,以及原料配比等因素对反应的影响。通过正交试验确定了适宜的合成工艺条件:反应温度0℃;反应时间6 h;对甲苯磺酰氯与(R)-(-)-3-氯-1,2-丙二醇摩尔比为1.2∶1;催化剂NaOH与(R)-(-)-3-氯-1,2-丙二醇的摩尔比为1.2∶1;以乙酸乙酯为溶剂,(R)-(-)-3-氯-1,2-丙二醇浓度为125 g/L。在此工艺条件下产物得率大于85%。 Synthesis of the medicinal intermediate (R)-(-)-3-chloro-2-hydroxypropyl tosylate was carried out by the reaction of (R)-(-)-3-chloro-1,2-propanediol and p-toluenesulfonyl chloride in this paper. The influences of the reaction temperature, reaction time, type and dosage of solvent, type and dosage of catalyst, and (R)- (-)-3-chloro-1,2-propanediol/p-toluenesulfonyl chloride ratio on the selectivity of esterification and yield of product were investigated. The suitable synthesis conditions were obtained by optimization with orthogonal experiments: reaction temperature 0℃, reaction time 6 h, the molar ratio of p-toluenesulfonyl chloride to (R)-(-)-3-chloro-1,2-propanediol 1.2:1, the molar ratio of catalyst NaOH to (R)-(-)-3-chloro-1,2-propanediol 1.2: 1. Ethyl acetate was used as solvent, and the concentration of (R)-(-)-3-chloro-1,2-propanediol was 125 g/L. The yield of (R)-(-)-3-chloro-2- hydroxypropyl tosylate was over 85 %.
出处 《南京林业大学学报(自然科学版)》 CAS CSCD 北大核心 2007年第6期34-38,共5页 Journal of Nanjing Forestry University:Natural Sciences Edition
关键词 (R)-(-)-3-氯-1 2-丙二醇 对甲苯磺酰氯 (R)-(-)-3-氯-2羟丙基对甲苯磺酸酯 (R)-(-)-3-chloro-1,2-propanediol p-toluenesulfonyl chloride (R)-(-)-3-chloro-2- hydroxypropyl tosylate
  • 相关文献

参考文献10

二级参考文献62

  • 1张苗,钱敏,魏建冬,孙诤,梅长林,徐洪实,顾书华.血透病人左旋肉碱缺乏及补充疗法的临床研究[J].江苏医药,1998,24(12):895-896. 被引量:1
  • 2张晓洁,刘惠兰.左旋肉毒碱(可益能)在血液透析患者中的临床应用研究[J].中国血液净化,2002,1(10):18-21. 被引量:28
  • 3施健,刘苏,谢渭芬.左旋卡尼汀与肝病[J].中华肝脏病杂志,2005,13(7):556-558. 被引量:15
  • 4[1]Evans AM,Fornasini G.Pharmocokinetics of L-carnitine.Clin Pharmocokinet,2003,42:941-967
  • 5[4]Neri S,Pistone G,Saraceno B,et al.L-Carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.Neuropsy chobiology,2003,47:94-97
  • 6[6]Selimoglu MA,Aydogdu S,Yagci RV,et al.Plasma and liver carnitine status of children with chronic liver disease and cirrhosis.Paediatri Int,2001,43:391-395
  • 7[7]Malaguarnera M,Pistone G,Astuto M,et al.L-Carnitine in the treatment of mild or moderate hepatic encephalopathy.Dig Dis,2003,21:271-275
  • 8Broquist HP, Borum PR. Carnitine biosynthesis: nutritional implications. Adv Nutr Res 1982, 4: 181-204
  • 9Rebouche CJ. Sites and regulation of carnitine biosynthesis in mammals. Fed Proc 1982, 41(12): 2848-2852
  • 10Cerretelli P, Marconi C.L-carnitine supple mentation in humans, The effects on physical performance. Int J Sports Med, 1990, 11(1): 14

共引文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部